Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019188 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00019188: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019188 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019188, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of interleukin-12 in treating patients with AIDS -related Kaposi's sarcoma.
Interventions
- DRUG interleukin-12
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019188
The ClinicalTrials.gov registry entry for NCT00019188 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which interleukin-12 is the first listed.
NCT00019188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019188 about?
NCT00019188 is a clinical study titled "Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma". RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of interleukin-12 in treating patients with AIDS -related Kaposi's sarcoma.
What is the current status of trial NCT00019188?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-01. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00019188?
The interventions under investigation include: interleukin-12 (DRUG).
Who is sponsoring clinical trial NCT00019188?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.